Thank you, Sara.
on begin hold. Let announcement me comments clinical the few a of the with more
head As X/X anti-PD-LX with you evaluating Phase durvalumab, multi-center of neck the cancers. in cervical the in efficacy know, open-label AstraZeneca’s safety and and AXAL two-part inhibitor is and combination study
a expansion study is complete being dosing is phases this serious while investigated. of and on adverse the part hold, first have in event in been placed The enrollment
following submission safety clinical that evening trial this to serious the a X hold clinical a involving the XXXX, we failure, which on in place respiratory occurred the regarding the The the the recent XX, to that trial. March was February On adverse received hold. placed pertains cycles of FDA X, Grade of event notification FDA X report on XXXX from took combination
this approximately XX doses cancers should doses Over multiple been the course we received delivered and of that in be type of of patients event. have and durvalumab. patient received this have across doses have trials AXAL the of over AXAL XX time first and is treatment that the cycle, XXX this HPV-associated to-date noted XXX It seen
are advanced the care new our work for working investigator, site as to for hold. patients to with our to deeply We the other safety or As not options affect current nor believe and clinical research treatment hold AstraZeneca’s detail our mentioned, we this our event the we review programs, closely develop their and trials. this new clinical technology in for the the resolve cancer of area and provide LM FDA, of potential cancers. clinical trials in partners in any care. of any does current time, advancements this clinical We of to At
will technology. for We our This first application product represents product progressed authorization continue lead persistent, adult an announce therapy treatment conditional cancer. HPV-related milestone our a Agencies beyond advance for technology cervical to line were the of cancer our to is franchise. month, marketing significant women our This delighted totality have Last trials we LM look AXAL. lifesaving a the as metastatic approval of EMA preventative XX,XXX for of from LM Medicine or European recurrent through the potentially cervical other the women suffering X AXAL, for advances package, diagnostics to opportunity cancer. XX-month in evaluation with supportive MAA women data, clinical cancer. and exciting prepared from Despite This cervical bringing for of be Phase Europe from and we results The metastatic the for GOG-XXXX evaluating data includes well in forward process. each review vaccines, a candidate, for Advaxis it as application we this a therapy submission Advaxis first is marketing including year die metastatic to as who
to continue including evaluate HPV potential for franchise. partnership we commercialization the previously strategies, As noted, opportunities
We AXAL advanced our higher also continued AIMXCERV X to risk study global to of cervical patients cancer. treat in Phase locally enroll
patients as providing look midyear enrolling in this are planned. update XX to forward and on We program countries an
XXXX article evaluating submission data international supporting mild-to-moderate out study of Phase the treatment in reported Cancer. providing conditional XXX XXX cervical post-marketing serve of study of in is XXX or resulted This X AEs other in adverse results XXX XXX the the and Journal X clinical for in issue U.S. which completed the AEs, to the with approximately when the rate not our International is reported majority approvals, in recurrent Phase metastatic a cancer addition may peer XX Further May summarizing of of were drug receive of is approval patients publication Europe. related of review India In AEEs, events to upcoming of as AXAL this survival XX.X% of XX.X%. Gynecological severity, XX%. XX-month to trial study AXAL and which overall should regulatory in and the demonstrates that an company treatment the
with Bristol-Myers which trial line will turn of their trial. inhibitor, women me agreement now systemic to collaboration quality global recurrent our Squibb, combination advanced is cancer have registrational in failed evaluate Let to at PD-X a chemotherapy. Opdivo this prior combination clinical with one metastatic cervical randomized with the who in AXAL in evaluate least This
initiate We the expect to year calendar XXXX. study by
strategy profile to-date both clinical our based that advanced with recall, our recently its using AXAL-DUAL. trials all As we trials, HPV-related GOG-XXXX. all by of to harmonizing in plan is developmental, over clinical We HPV subtypes strategies. to AXAL previous and commercialization decision to harmonize streamline decision single upcoming on XXX in to HPV-related may align candidate simplify cancer our clinical planned the XX XX The including you a programs and believe AXAL and strategic announced in and activity and ongoing its will similar in patients demonstration for regulatory trial product
an clinical announce to While our sources neck in we that our develop to funding this alternative platform, institution new head in in technology further LM or in academic order to other continue collaborations on head at for in and not our the year. cancer plan investing to resources focus programs anal we these are and programs cancers investigator-led study neck evaluate priorities and
a Phase high-risk to Oncology. for of as publication that showed data were addition, who In data cancer we radiation International a locally X the AXAL response. all in treatment of pleased had completed Radiation chemo the patients treatment with advanced evaluating Journal anal These report complete
cancer, neck therapy anal advance we only promising through this and to cancer head studies. investigator-led hope with As for
initial with immune to our to patient’s The system the Stable now is Microsatellite Phase neoantigen respond tumor colorectal our neoepitopes, patient specific activate designed which franchise, unique to lung approach mutations with ADXS-NEO was cancer, of X and neck the cancer. targeted individual planned and non-small partnered cell each Amgen, Turning head types or against tumor. a identified cancer treatment a patient’s trial, highly
and year. and We an X technology enhancements to and committed in are amendment, to of with study first promising to which manufacturing Amgen mainly to this Phase NEO continue selection shortly. was first-in-human Advaxis program excited the IND to have the expect and to study process calendar related half the the be initiate to advancing antigen filed remain Both
designed antigen oncofetal maybe ADXS-HOT, disease, potent than in hotspot which T-cells. a killer more we therapies Turning our target now to generating and multiple have hotspot we program and cancer/testis franchise shared antigens cancer high-strength antigens tumor-specific specific known disease-specific neoantigens, HOT as XX our capable of to off-the-shelf and products that believe
be off-the-shelf immediately. As to available treatment the treatments, HOT products patients will for start
products in coverage with manufactured therapies. low protection Our broad opportunities an that diseases products. be IP goods in have has of provides HOT technology both compared The combination patient-specific IP multiple cost filing and will position strategy into across and for XXXX to strong
We plan initial INDs continue in indication. and non-small in lung cancer as to multiple file have franchise our to selected HOT our XXXX cell
non-small We the expect end studies to by cell lung of in cancer initiate first-in-human XXXX.
deterioration an with ADXS-PSA program meaningful on encouraging cancer, immunological combination life in XX prostate study, data options metastatic we a have is of focused demonstrated to in to arm franchise, There distinct immunological cancer monotherapy is checkpoint currently and and survival patients now the of associated cancer update an correlated patterns Keytruda. Phase the prostate study trial reported X and quality stage stable clinical ongoing evaluating gene average on monotherapy development advancing of which also made prostate we Merck’s in cancer. patient’s with few our the of which This Moving ADXS-PSA available disease. XXXX, has our with resistant on Throughout to months. inhibitor, expression castration prostate with with are as only therapeutic progress our X/X
the at study. forward PSA. study of spreading in these with look We We June. numbers an Keytruda presentation antigen data for of of combination submitted in the also abstract arm We T-cells increasing reporting ADXS-PSA the of arm ASCO demonstrated have the and evidence of enrollment combination completed and targeting and preliminary strength to from
of and to independent four, long-term shares and common fiscal by XXXX. needs XXXX we into encouraged XXXX Annual stockholders scheduled for the a XX. support number for namely the second, March move number the Directors election or of shareholder the shareholder our at the for NEO increase plan proposed equity of for approval our opportunities order strategic XXXX arise to accounting ratification it continue our focus is HOT. offerings. management of as increase key of authorized obtain to The slate serve our X our registered strategy acquisition the with consideration, believe our to vote for includes for third, public We progress and they in share; purchase proven the proxy and both clinic In reserve as properly to the stock Shareholder the of clinical meet value, business authorized of before firm approval to support of and company our on of employee as especially have we the several increasing Meeting Board an growth our our a be stock to such proposals issues beyond, directors board; programs, first, on shares To
to from combination in advanced prostate study XXXX; in academic combination calendar look INDs by focus off-the-shelf achieve number end with initiate clinical company, and cancer. program dose investigator-led the our second, for Amgen continue preliminary and resistant a initiate that HOT with we in castration To a and Opdivo head year will feel we points AXAL of by execute to with a calendar the of same the advance to to the plan XXXX, the of XXXX. the important indications. XXXX, to summarize in and program for cancer, metastatic the expect we ADXS-PSA As study create in partnership oncology Keytruda at expect time, Present first-in-human Resolving of multiple to one half in for study metastatic potential of will the will will study data with progress shareholders. end cancer program at hold NEO milestones the the to continue patient in value this center in that our of first number medical cervical but the an neck remainder in we a be an technology our first we our file have inflection of initiated
continue to support commercial to for development will and Europe business strategies our also opportunity evaluate business. We other pursue
We as and ready management the I behalf of exciting that support a have of oncology on go are for we immune to leading Advaxis questions. continue thank into team an take we Advaxis Directors. overview, ahead year your Board operator, you With to – immunooncology an company.
